This inventor holds 2 USPTO granted patents. Top assignee: Megabios Corporation. Active years: 2000-2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000-2001
Title: Ralph Niven: Innovator in Nucleic Acid Delivery
Introduction
Ralph Niven is a notable inventor based in Redwood City, CA (US). He has made significant contributions to the field of molecular biology, particularly in the area of nucleic acid delivery systems. With a total of 2 patents, Niven's work has the potential to impact various applications in genetic research and therapeutic development.
Latest Patents
Niven's latest patents include innovative methods for introducing nucleic acids into mammalian cells using imidazolium lipids. These methods utilize imidazolium lipids that have a specific chemical formula, enhancing the efficiency of nucleic acid delivery. Another patent focuses on compositions and methods using novel substituted imidazolium lipids, which are characterized by compounds that feature hydrocarbon chains and various heteroatom moieties. This research is crucial for advancing techniques in gene therapy and molecular biology.
Career Highlights
Ralph Niven is currently associated with Megabios Corporation, where he continues to develop and refine his innovative approaches to nucleic acid delivery. His work is instrumental in pushing the boundaries of what is possible in genetic engineering and therapeutic applications.
Collaborations
Niven collaborates with talented individuals such as Jinkang Wang and Yilin Zhang, who contribute to the research and development efforts at Megabios Corporation. Their combined expertise fosters a dynamic environment for innovation.
Conclusion
Ralph Niven's contributions to the field of nucleic acid delivery through his patents and collaborations highlight his role as a key innovator in biotechnology. His work continues to pave the way for advancements in genetic research and therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile